Key Clinical Updates with HER2-Targeting Therapies

Panelists are going to discuss recent updates in the treatment of breast cancer, focusing on the key updates for HER2-targeting therapies. We will discuss the data in the context of the evolving landscape and its impact on clinical practice.

EP. 1: Background Information on Targeted Therapies in Breast Cancer

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

EP. 2: Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

EP. 3: The Role of ADCs in Different Subgroups

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

EP. 4: First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

EP. 5: Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

EP. 6: Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

November 18th 2025

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

EP. 7: Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

November 25th 2025

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

EP. 8: Disease State Information on TNBC

November 25th 2025

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

EP. 9: Exciting New Data for TNBC Therapies

December 4th 2025

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

EP. 10: Unmet Needs and Future Outlook for HER2-Targeted Therapies

December 4th 2025

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.